Emergent Biosolutions (NYSE:EBS) Announces Earnings Results

Emergent Biosolutions (NYSE:EBS) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68, FiscalAI reports. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The firm had revenue of $234.30 million during the quarter, compared to analyst estimates of $177.50 million.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Q2 results exceeded expectations, with revenue of $234 million and adjusted EBITDA of $97 million, up from $33 million a year earlier. Medical countermeasure deliveries to U.S. government customers were accelerated, driving much of the outperformance.
• The medical countermeasures business remains a key growth driver, with Q2 revenue of $168 million and new contract modifications totaling $117.2 million for ACAM2000 and botulism antitoxin. International MCM sales represented about 20% of first-half MCM revenue.
• Emergent lowered 2026 revenue guidance to $645 million-$675 million from $720 million-$760 million and reduced adjusted EBITDA guidance to $130 million-$150 million, citing increased competition, pricing pressure, and volume pressure in the naloxone market.
• The company recorded a $191 million non-cash impairment charge against its NARCAN asset group and expects further price erosion as new nasal naloxone competitors enter the market. Emergent said total naloxone unit demand may remain roughly flat while it works to defend its more-than-50% market share.
• Emergent is restructuring to generate approximately $40 million in annualized savings, including about 90 job reductions, facility closures, and other footprint changes; most savings are expected to be realized in 2027. Liquidity also improved through accounts-receivable collections, debt refinancing, and lower gross debt.

Emergent Biosolutions Stock Performance

NYSE:EBS traded down $0.01 during trading hours on Wednesday, reaching $7.55. 707,748 shares of the stock were exchanged, compared to its average volume of 659,451. The stock has a market capitalization of $389.84 million, a P/E ratio of -26.98 and a beta of 2.35. The firm has a 50 day simple moving average of $7.98 and a 200-day simple moving average of $8.83. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. Emergent Biosolutions has a 52 week low of $6.03 and a 52 week high of $14.06.

Insider Buying and Selling at Emergent Biosolutions

In related news, SVP Paul Anthony Williams sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.

Institutional Trading of Emergent Biosolutions

Several institutional investors have recently added to or reduced their stakes in EBS. Legal & General Group Plc bought a new position in shares of Emergent Biosolutions in the 2nd quarter worth about $31,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of Emergent Biosolutions during the 4th quarter valued at about $45,000. Raymond James Financial Inc. bought a new stake in shares of Emergent Biosolutions during the 2nd quarter valued at about $53,000. BNP Paribas Financial Markets grew its position in shares of Emergent Biosolutions by 133.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,942 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 6,246 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in Emergent Biosolutions during the fourth quarter worth about $107,000. Institutional investors own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

EBS has been the subject of several research analyst reports. Weiss Ratings cut Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Emergent Biosolutions presently has a consensus rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.